Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-04-23 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于回购股份首次实施的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first implementation of a share repurchase program, detailing the number of shares bought back, the price, and the total amount spent. It references prior board and shareholder meetings approving the repurchase and provides specific transaction details. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares. The document is short and focused solely on the repurchase transaction, not a broader financial report or other type of filing.
2018-04-23 Chinese
2017年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2017 Annual General Meeting Resolution Announcement" for Kunming Pharmaceutical Group Co., Ltd. It details the resolutions passed at the 2017 Annual General Meeting (AGM) held on April 20, 2018, including voting results on various agenda items such as the 2017 board work report, financial report, profit distribution, appointment of auditors, and other corporate matters. The document includes attendance details, voting percentages, and legal witness statements confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements but rather the official announcement of the AGM resolutions and voting outcomes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 5578 characters, which is sufficient to include detailed voting results and meeting information, not just a brief announcement. Hence, the classification is DVA with high confidence.
2018-04-20 Chinese
2017年年度股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion from a law firm regarding the 2017 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd. It discusses the legality and procedures of the AGM, including the convening, attendance, voting procedures, and resolutions passed. It does not contain the actual AGM materials or presentations but rather a legal review and confirmation of the AGM's compliance with laws and company bylaws. This type of document is best classified under Declaration of Voting Results & Voting Rights Announcements (DVA) because it reports on the voting results and legality of the AGM proceedings.
2018-04-20 Chinese
关于媒体报道公司硫酸庆大注射液GMP证书被收回的说明公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding a media report about the revocation of the GMP certificate for a specific product (sulfate gentamicin injection). It discusses regulatory issues, the company's response, and potential impacts on business. The document is short (895 characters) and serves as a public disclosure of a regulatory matter rather than a detailed financial report or audit. It does not contain financial statements or detailed management analysis. It is not a report publication announcement since it contains substantive information about the regulatory issue and company response. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about compliance and investigation status.
2018-04-13 Chinese
八届五十一次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 51st meeting of the 8th board, including approval of the 2018 Q1 report, financing plans, and a share acquisition. The document is a formal announcement of board decisions rather than the full report itself. It includes voting results and references to management and financing decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (1139 characters), and it is not a full financial report or earnings release. Therefore, the classification is MANG with high confidence.
2018-04-12 Chinese
2018年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2018 年第一季度报告' which translates to '2018 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2018. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited financial statements and management commentary on financial changes and business activities during the quarter. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2018
2018-04-12 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.